COVID-19

FMT: Can It Improve Immunotherapy Outcomes?

Further research is warranted to understand the potential ways fecal microbiota transplantations may improve patients’ responses to immunotherapy.

Antithrombotic Therapy Not Helpful for COVID-19 Outpatients

Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients.

Potential Safety Concern for Guillain-Barré Syndrome Associated With Ad26.COV2.S Vaccine

Based on preliminary findings for presumptive GBS, overall observed-to-expected rate ratio estimated to be 4.18 for 42-day window.

More Than Half of COVID-19 Survivors Have Postacute Sequelae

Most common sequelae include functional mobility impairments, pulmonary abnormalities, and mental health disorders.

Disparities Found in Vaccination Coverage by Age 24 Months Before COVID-19

Disparities in coverage for race/ethnicity, poverty status, health insurance status seen among children born in 2017 to 2018.

COVID-19 Vaccines Safe and Well Tolerated Among Patients With Juvenile Idiopathic Arthritis Receiving TNF Inhibitors

Researchers evaluated the safety and tolerability of the BNT162b2 COVID-19 vaccine in adolescents with juvenile idiopathic arthritis receiving TNF inhibitors.

Vaccinated Foreign Travelers Can Enter United States Beginning Nov. 8

Foreign air travelers to the U.S. are required to have full vaccination, proof of negative test before boarding, and follow-up negative test within three days of entering U.S.

FDA Panel Recommends Approval of Johnson and Johnson Booster Shot

The booster shot is recommended for anyone 18 years and older, to be given at least two months after the first dose

Incidence Rates of SARS-CoV-2 Similar for Children and Adults

More infections asymptomatic among children, with 52 percent asymptomatic among those aged 0 to 4 years versus 12 percent in adults.

COVID-19 and Cardiogenic Shock

The authors describe how to diagnose and treat comorbid cardiogenic shock and COVID-19 in this case study.